We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Boston Scientific (BSX) Ascends While Market Falls: Some Facts to Note
Read MoreHide Full Article
Boston Scientific (BSX - Free Report) ended the recent trading session at $76.85, demonstrating a +1.45% change from the preceding day's closing price. This change outpaced the S&P 500's 0.43% loss on the day. Elsewhere, the Dow saw a downswing of 1.05%, while the tech-heavy Nasdaq depreciated by 0.92%.
Shares of the medical device manufacturer have depreciated by 17.96% over the course of the past month, underperforming the Medical sector's loss of 1.34%, and the S&P 500's loss of 0.5%.
The investment community will be closely monitoring the performance of Boston Scientific in its forthcoming earnings report. It is anticipated that the company will report an EPS of $0.79, marking a 5.33% rise compared to the same quarter of the previous year. Alongside, our most recent consensus estimate is anticipating revenue of $5.19 billion, indicating a 11.29% upward movement from the same quarter last year.
Regarding the entire year, the Zacks Consensus Estimates forecast earnings of $3.46 per share and revenue of $22.32 billion, indicating changes of +13.07% and +11.16%, respectively, compared to the previous year.
Investors should also take note of any recent adjustments to analyst estimates for Boston Scientific. Such recent modifications usually signify the changing landscape of near-term business trends. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the business health and profitability.
Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. The Zacks Consensus EPS estimate has moved 0.36% higher within the past month. Boston Scientific is currently a Zacks Rank #3 (Hold).
With respect to valuation, Boston Scientific is currently being traded at a Forward P/E ratio of 21.91. This indicates a premium in contrast to its industry's Forward P/E of 20.66.
One should further note that BSX currently holds a PEG ratio of 1.05. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. Medical - Products stocks are, on average, holding a PEG ratio of 1.78 based on yesterday's closing prices.
The Medical - Products industry is part of the Medical sector. At present, this industry carries a Zacks Industry Rank of 139, placing it within the bottom 44% of over 250 industries.
The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Don't forget to use Zacks.com to keep track of all these stock-moving metrics, and others, in the upcoming trading sessions.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Boston Scientific (BSX) Ascends While Market Falls: Some Facts to Note
Boston Scientific (BSX - Free Report) ended the recent trading session at $76.85, demonstrating a +1.45% change from the preceding day's closing price. This change outpaced the S&P 500's 0.43% loss on the day. Elsewhere, the Dow saw a downswing of 1.05%, while the tech-heavy Nasdaq depreciated by 0.92%.
Shares of the medical device manufacturer have depreciated by 17.96% over the course of the past month, underperforming the Medical sector's loss of 1.34%, and the S&P 500's loss of 0.5%.
The investment community will be closely monitoring the performance of Boston Scientific in its forthcoming earnings report. It is anticipated that the company will report an EPS of $0.79, marking a 5.33% rise compared to the same quarter of the previous year. Alongside, our most recent consensus estimate is anticipating revenue of $5.19 billion, indicating a 11.29% upward movement from the same quarter last year.
Regarding the entire year, the Zacks Consensus Estimates forecast earnings of $3.46 per share and revenue of $22.32 billion, indicating changes of +13.07% and +11.16%, respectively, compared to the previous year.
Investors should also take note of any recent adjustments to analyst estimates for Boston Scientific. Such recent modifications usually signify the changing landscape of near-term business trends. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the business health and profitability.
Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. The Zacks Consensus EPS estimate has moved 0.36% higher within the past month. Boston Scientific is currently a Zacks Rank #3 (Hold).
With respect to valuation, Boston Scientific is currently being traded at a Forward P/E ratio of 21.91. This indicates a premium in contrast to its industry's Forward P/E of 20.66.
One should further note that BSX currently holds a PEG ratio of 1.05. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. Medical - Products stocks are, on average, holding a PEG ratio of 1.78 based on yesterday's closing prices.
The Medical - Products industry is part of the Medical sector. At present, this industry carries a Zacks Industry Rank of 139, placing it within the bottom 44% of over 250 industries.
The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Don't forget to use Zacks.com to keep track of all these stock-moving metrics, and others, in the upcoming trading sessions.